Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Childhood Cancers Clear all
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

NCT01118013
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, donor lymphocytes, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, reduced-intensity transplant conditioning procedure, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Early Phase 1 Interventional Results available

Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain

NCT00452868
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity
Interventions
Donepezil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

NCT00079404
View directory record Official record
Conditions
Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
tanespimycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jun 10, 2026, 9:32 PM EDT
Terminated No phase listed Observational

Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

NCT00949052
View directory record Official record
Conditions
Cancer
Interventions
DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
Genetic · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

NCT00027846
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
filgrastim, carboplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy, Mesna, therapeutic conventional surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
140
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 118 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jun 10, 2026, 9:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

NCT01089101
View directory record Official record
Conditions
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1, Recurrent Visual Pathway Glioma, Refractory Neurofibromatosis Type 1, Refractory Visual Pathway Glioma
Interventions
Biospecimen Collection, Selumetinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 10, 2026, 9:32 PM EDT
Terminated Early Phase 1 Interventional

Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia

NCT00020670
View directory record Official record
Conditions
Leukemia
Interventions
CD 40
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jun 10, 2026, 9:32 PM EDT
Recruiting Not applicable Interventional

Evaluation Of Cardiovascular Health Outcomes Among Survivors 2

NCT07245420
View directory record Official record
Conditions
Health Behavior
Interventions
Survivorship Care Plan + Educational Materials (delivered via CIAS platform), Healthy Hearts eHealth Program
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
26 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

NCT01321346
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
Panobinostat, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
8 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Jun 10, 2026, 9:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

NCT03817320
View directory record Official record
Conditions
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Interventions
Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Jun 10, 2026, 9:32 PM EDT
Active, not recruiting No phase listed Observational

Social Experiences of Adolescents and Young Adults With Cancer

NCT04328350
View directory record Official record
Conditions
Childhood Cancer, Social Behavior, Social Competence
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
15 Years to 22 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 10, 2026, 9:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

DNA Variations in the Gene in Young Patients With Wilms' Tumor

NCT00088803
View directory record Official record
Conditions
Kidney Cancer
Interventions
molecular genetic technique, polymerase chain reaction, polymorphism analysis
Genetic
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
471 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
205
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Phase 3 Interventional

Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer

NCT00112996
View directory record Official record
Conditions
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
alpha-lipoic acid, placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
13
States / cities
Fort Smith, Arkansas • Lafayette, Indiana • Wichita, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Not applicable Interventional

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00003538
View directory record Official record
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

NCT00253513
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
fludarabine, treosulfan, allogeneic blood or bone marrow transplantation
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors

NCT00003241
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
phenylacetate
Drug
Lead sponsor
Texas Children's Cancer Center
Other
Eligibility
2 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Jun 10, 2026, 9:32 PM EDT
Completed No phase listed Observational

Psychosocial Impact of Disclosing Cancer Predisposition Genetic Testing Results During Childhood

NCT04848142
View directory record Official record
Conditions
Pediatric Cancer, Predisposition, Genetic
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Not applicable Interventional Results available

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

NCT00058370
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cisplatin, lomustine, vincristine sulfate, adjuvant therapy, iodine I 131 monoclonal antibody 3F8, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Jun 10, 2026, 9:32 PM EDT
Completed No phase listed Observational

Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia

NCT01150669
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 2 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Jun 10, 2026, 9:32 PM EDT
Available No phase listed Expanded access

131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

NCT01163383
View directory record Official record
Conditions
Neuroblastoma, Childhood Metastatic Pheochromocytoma
Interventions
131 I-Metaiodobenzylguanidine (131 I-MIBG), 131 I-MIBG
Drug
Lead sponsor
John Maris
Other
Eligibility
1 Year and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

Gemcitabine in Treating Children With Refractory Solid Tumors

NCT00005577
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gemcitabine hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Jun 10, 2026, 9:32 PM EDT
Terminated Phase 1 Interventional

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

NCT00087009
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder
Interventions
beta-glucan, rituximab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

NCT00004228
View directory record Official record
Conditions
Lymphoma
Interventions
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
152
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Jun 10, 2026, 9:32 PM EDT
Completed Not applicable Interventional Results available

Feasibility of a Self-Management + Peer Mentoring Intervention for Adolescent and Young Adult Childhood Cancer Survivors

NCT04075734
View directory record Official record
Conditions
Childhood Cancer Survivors
Interventions
Managing Your Health: Self-Management + Peer Mentoring
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 29 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Jun 10, 2026, 9:32 PM EDT